| Literature DB >> 29329277 |
Gina Vasile Scăețeanu1, Mariana Carmen Chifiriuc2,3, Coralia Bleotu4, Crina Kamerzan5,6,7, Luminiţa Măruţescu8,9, Constantin G Daniliuc10, Cătălin Maxim11, Larisa Calu12, Rodica Olar13, Mihaela Badea14.
Abstract
The synthesis, structural characterization, cytotoxicity, and antimicrobial properties of four new complexes formed by employing acrylate anion and 2,2'-bipyridine are reported herein. X-ray crystallography revealed the trinuclear nature of [Mn₃(2,2'-bipy)₂(C₃H₃O₂)₆] (1), meanwhile complexes with general formula [M(2,2'-bipy)(C₃H₃O₂)₂(H₂O)x]∙yH₂O ((2) M: Ni, x = 1, y = 0; (3) M: Cu, x = 1, y = 0; (4) M: Zn, x = 0, y = 1; 2,2'-bipy: 2,2'-bipyridine; C₃H₃O₂: acrylate anion) were shown to be mononuclear. The lowest minimum inhibitory concentration (MIC) of 128 μg mL-1 was recorded for all four tested complexes against Candida albicans, for complex (3) against Escherichia coli, and for complex (4) against Staphylocococcus aureus. Compounds (3) and (4) were also potent efflux pumps activity inhibitors (EPI), proving their potential for use in synergistic combinations with antibiotics. Complexes (1)-(4) revealed that they were not cytotoxic to HCT-8 cells. They also proved to interfere with the cellular cycle of tumour HCT-8 cells by increasing the number of cells found in the S and G2/M phases. Taken together, these results demonstrate the potential of zinc and copper complexes for use in the development of novel antimicrobial and anti-proliferative agents.Entities:
Keywords: 2,2′-bipyridine complexes; acrylato ligand; antifungal activity; trinuclear complex
Mesh:
Substances:
Year: 2018 PMID: 29329277 PMCID: PMC6017882 DOI: 10.3390/molecules23010157
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Crystal data and structure refinement for complexes (1)–(4).
| 1 | 2 | 3 | 4 | |
|---|---|---|---|---|
| Empirical formula | Mn3C38H34N4O12 | NiC16H16N2O5 | CuC16H16N2O5 | ZnC16H14N2O4 |
| Formula weight | 903.51 | 375.02 | 379.85 | 363.66 |
| Temperature (K) | 223(2) | 293(2) | 223(2) | 293(2) |
| Wavelength λ (Å) | 0.71073 | 0.71073 | 0.71073 | 0.71073 |
| Crystal system | triclinic | monoclinic | monoclinic | orthorhombic |
| Space group | ||||
| a (Å) | 10.9974(2) | 11.850(2) | 21.7184(5) | 30.2270(16) |
| b (Å) | 14.0231(3) | 16.442(3) | 7.0006(2) | 7.3771(3) |
| c (Å) | 14.5373(4) | 9.386(2) | 21.7462(4) | 14.9842(7) |
| α (°) | 102.497(1) | 90 | 90 | 90 |
| β (°) | 99.771(1) | 113.33(3) | 100.914(1) | 90 |
| γ (°) | 109.161(1) | 90 | 90 | 90 |
| Volume (Å3) | 1995.9(1) | 1679.2(6) | 3246.5(1) | 3341.3(3) |
| Z | 2 | 4 | 8 | 8 |
| Reflections collected | 30,120 | 27,530 | 21,831 | 52,963 |
| Independent reflections | 7889 [Rint = 0.039] | 3424 [Rint = 0.121] | 7823 [Rint = 0.049] | 5992 [Rint = 0.0704] |
| Goodness of fit on F2 | 1.037 | 1.054 | 1.029 | 0.887 |
| 1.503 | 1.483 | 1.554 | 1.446 | |
| μ (mm−1) | 1.001 | 1.183 | 1.374 | 1.490 |
| R(Fo), [I > 2σ(I)] | 0.041 | 0.050 | 0.049 | 0.031 |
| Rw (Fo2) | 0.114 | 0.102 | 0.131 | 0.063 |
| ∆ | 0.62/−0.44 | 0.43/−0.48 | 1.12/−0.55 | 0.21/−0.19 |
Figure 1X-ray structure of [Mn3(2,2′-bipy)2(C3H3O2)6] (1). Thermal ellipsoids are shown with 30% probability.
Selected bond lengths (Å) and angles (°) for [Mn3(2,2′-bipy)2(C3H3O2)6] (1).
| Mn1–O3 | 2.0898(16) | N2–Mn1–N1 | 72.48(7) |
| Mn1–O1 | 2.1026(16) | O4–Mn2–O5 | 87.99(6) |
| Mn1–O5 | 2.1263(15) | O4–Mn2–O9 | 91.68(6) |
| Mn1–N2 | 2.2091(17) | O5–Mn2–O9 | 91.81(6) |
| Mn1–N1 | 2.2670(2) | O4–Mn2–O11 | 91.25(6) |
| Mn2–O4 | 2.1613(15) | O5–Mn2–O11 | 179.22(6) |
| Mn2–O5 | 2.1669(14) | O9–Mn2–O11 | 88.04(6) |
| Mn2–O9 | 2.1692(15) | O4–Mn2–O7 | 177.46(5) |
| Mn2–O11 | 2.1707(14) | O5–Mn–O7 | 90.18(6) |
| Mn2–O7 | 2.1711(15) | O9–Mn2–O7 | 90.14(6) |
| Mn2–O2 | 2.1862(14) | O11–Mn2–O7 | 90.59(6) |
| Mn3–O8 | 2.0813(17) | O4–Mn2–O2 | 88.73(6) |
| Mn3–O10 | 2.0829(16) | O5–Mn2–O2 | 88.50(6) |
| Mn3–O11 | 2.1379(14) | O9–Mn2–O2 | 179.50(5) |
| Mn3–N3 | 2.2152(16) | O11–Mn2–O2 | 91.66(6) |
| Mn3–N4 | 2.2634(18) | O7–Mn2–O2 | 89.46(6) |
| O8–Mn3–O10 | 95.92(7) | ||
| O3–Mn1–O1 | 95.55(7) | O8–Mn3–O11 | 99.80(6) |
| O3–Mn1–O5 | 98.73(7) | O10–Mn3–O11 | 105.90(6) |
| O1–Mn1–O5 | 109.51(6) | O8–Mn3–N3 | 92.10(6) |
| O3–Mn1–N2 | 95.43(6) | O10–Mn3–N3 | 111.17(6) |
| O1–Mn1–N2 | 112.03(6) | O11–Mn3–N3 | 139.54(6) |
| O5–Mn1–N2 | 134.31(6) | O8–Mn3–N4 | 164.53(6) |
| O3–Mn1–N1 | 167.37(7) | O10–Mn3–N4 | 92.61(7) |
| O1–Mn1–N1 | 92.49(7) | O11–Mn3–N4 | 90.20(6) |
| O5–Mn1–N1 | 87.69(7) | N3–Mn3–N4 | 72.76(6) |
Figure 2Carboxylate bridging mode in trinuclear complexes with the general formula [Mn3(RCOO)6(N–N)2] [42].
Structural parameters (Å) for trinuclear compounds of the type [Mn3(RCOO)6(2,2′-bipy)2] and carboxylate bridging mode.
| Compound | d(Mnc‒Ob) | d(Mnt‒Ob) | d(Mnt‒Od) | d(Mn…Mn) | Carboxylate Bridging Mode | Ref |
|---|---|---|---|---|---|---|
| [Mn3((CH3)2CHCOO)6(2,2′-bipy)2] | 2.177 | 2.173 | 2.471 | 3.489 | A | [ |
| [Mn3(C6H5CH=CHCOO)6(2,2′-bipy)2]·H2O | 2.221 | 2.218 | 2.388 | 3.527 | A | [ |
| [Mn3(CH2=CHCOO)6(2,2′-bipy)2] ( | 2.170 | 2.132 | 2.722 | 3.476 | B | this paper |
| [Mn3(CH3COO)6(2,2′-bipy)2] | 2.202 | 2.155 | 2.605 | 3.614 | B | [ |
| [Mn3(ClCH2COO)6(2,2′-bipy)2] | 2.217 | 2.151 | 2.611 | 3.624 | B | [ |
Figure 3X-ray structure of [Ni(2,2′-bipy)(C3H3O2)2(H2O)] (2). Thermal ellipsoids are shown with 30% probability.
Figure 4Packing diagram presenting the C–HO hydrogen bonds and ππ interactions along the a-axis in complex (2).
Figure 5X-ray structure of [Cu(2,2′-bipy)(C3H3O2)2(H2O)] (3). Thermal ellipsoids are shown with 30% probability. (Only molecule “A” of the two found in the asymmetric unit is shown).
Figure 6Packing diagram presenting the O–HO hydrogen bond and ππ interactions along the b-axis in complex (3).
Figure 7X-ray structure of [Zn(2,2′-bipy)(C3H3O2)2]·H2O (4). Thermal ellipsoids are shown with 15% probability. (Only molecule “A” of two found in the asymmetric unit is shown).
Figure 8Packing diagram presenting the π…π interactions along the b-axis in complex (4).
Selected bond lengths (Å) and angles (°) in 2, 3, and 4.
| 2 | 3* | 4* | |
|---|---|---|---|
| M–N1 | 2.075(3) | 2.021(3)/2.019(3) | 2.100(3)/2.093(2) |
| M–N2 | 2.064(3) | 2.012(3)/2.009(3) | 2.099(2)/2.100(3) |
| M–O1 | 2.126(2) | 1.991(3)/1.982(3) | 1.994(3)/2.012(3) |
| M–O2 | 2.147(3) | 2.637(3)/2.679(3) | 2.490(3)/2.370(4) |
| M–O3 | 2.034(2) | 1.949(3)/1.957(3) | 2.032(3)/1.977(3) |
| M–O4 | - | -/- | 2.326(3)/2.563(3) |
| M–O5w | 2.060(3) | 2.289(3)/2.281(3) | -/- |
| N1–M–N2 | 79.3(1) | 80.5(1)/80.4(1) | 78.7(1)/78.7(1) |
* Two independent molecules were found in the asymmetric unit.
Selected bond lengths for complexes (2)–(4) and similar species.
| Complex | Bond Lengths (Å) | Reference | ||
|---|---|---|---|---|
| M–N | M–O (Carboxylate) | M–O (Water) | ||
| [Ni(2,2′-bipy)(C3H3O2)2(H2O)] ( | 2.075(3) | 2.034(2) | 2.060(3) | this paper |
| [Ni(2,2′-bipy)(O2CMe)2(H2O)2] | 2.069(2) | 2.079(2) | 2.082(2) | [ |
| [Ni(dmbipy)(O2CMe)2(H2O)2] | 2.067(4) | 2.077(3) | 2.077(3) | |
| [Cu(2,2′-bipy)(C3H3O2)2(H2O)] ( | 2.021(3)/2.019(3) | 1.976(4) | 2.289(3)/2.281(3) | this paper |
| [Cu(2,2′-bipy)2(O2CPh)]I·0.5H2O | 1.987(4) | 1.991(3)/1.982(3) 2.637(3)/2.679(3) | - | [ |
| [Cu(2,2′-bipy)(C4H5O2)2(H2O)] | 2.023(3) | 1.969(2)/1.926(2) | 2.292(2) | [ |
| [Cu(2,2′-bipy)2(O2CMe)]ClO4 | 2.033(19), 1.998(18) | 1.997(17) | - | [ |
| [Zn(2,2′-bipy)(C3H3O2)2]·H2O ( | 2.100(3)/2.093(2) | 1.994(3)/2.012(3) | - | this paper |
| [Zn(dmbipy)(O2CMe)2] | 2.079(2) | 2.058(2) | [ | |
dmbipy: 4,4′-dimethyl-2,2′-bipyridine; C4H5O2: methacrylate ion.
Minimum inhibitory concentration (μg mL−1) values recorded for complexes (1)–(4), sodium acrylate, and standard antibiotics.
| Strains | Gram-Positive Bacterial Strain | Gram-Negative Bacterial Strain | Fungal Strain | |
|---|---|---|---|---|
| Compound | ||||
| ( | 512 | 256 | 128 | |
| ( | 1024 | 1024 | 128 | |
| ( | 512 | 128 | 128 | |
| ( | 128 | 1024 | 128 | |
| 5000 | 5000 | 5000 | ||
| 0.5 | 0.05 | |||
| 0.5 | ||||
* CIP: ciprofloxacin; AMB: amphotericin B.
Figure 9The effects of 10µg/mL (left histograms) or 1 µg/mL (middle histograms) compounds on the HCT8 cell cycle progression. In the right is represented the overlaid histograms of treated and untreated HCT8 cells.